Reverse Acquisition (Tables)

12 Months Ended

Dec. 31, 2012

Reverse Acquisition [Abstract]

Schedule of Purchase Price Allocation

Based on the final purchase price allocation, the following table summarizes the fair value amounts of the assets acquired and liabilities assumed at the date of the acquisition:

	(Restated)
Cash and cash equivalents	$	1,271
Accounts receivable		1,873
Inventories		7,136
Prepaid expenses and other current assets		639
Property and equipment		4,543
Patents and licensed technologies		13,500
Other intangible assets		12,000
Other assets		41
Deferred tax assets		28,589
Total assets acquired at fair value		69,592
Accounts payable		(6,333	)
Accrued compensation and related expenses		(1,554	)
Other accrued liabilities		(2,592	)
Deferred revenues		(556	)
Total liabilities assumed		(11,035	)
Net assets acquired	$	58,557

Unaudited pro-forma results

The consolidated results of operations do not include any revenues or expenses related to the pre-merged PhotoMedex business on or prior to December 13, 2011, the consummation date of the reverse acquisition. The Company's unaudited pro-forma results for the years ended December 31, 2011 and 2010 summarize the combined results of the Radiancy and PhotoMedex in the following table, assuming the reverse acquisition had occurred on January 1, 2010 and after giving effect to the reverse acquisition adjustments, including amortization of the tangible and intangible assets that were acquired in the transaction:

	Year Ended December 31,
	2011			2010
	(unaudited)			(unaudited)
Net revenues	$	162,341		$	104,872
Net income (loss)		(13,077	)		6,378
Net income (loss) per share:
Basic	$	(0.91	)	$	0.50
Diluted	$	(0.91	)	$	0.45
Shares used in calculating net income (loss) per share:
Basic		14,445,184			13,845,883
Diluted		14,445,184			14,314,292